Rapid Increase in SARS-CoV-2 P.1 Lineage Leading to Codominance with B.1.1.7 Lineage, British Columbia, Canada, January-April 2021.

British Columbia COVID-19 Canada January–April 2021. Emerg Infect Dis. 2021 Nov [date cited]. https://doi.org/10.3201/eid2711.211190 Jassem AN Joffres Y Noftall K SARS-CoV-2 Sbihi H Suggested citation for this article: Hogan CA Tyson JR coronavirus disease et al. Rapid increase in SARS-CoV-2 P.1 lineage leading to codominance with B.1.1.7 lineage public health respiratory infections severe acute respiratory syndrome coronavirus 2 testing variant of concern viruses zoonoses

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
11 2021
Historique:
pubmed: 14 8 2021
medline: 28 10 2021
entrez: 13 8 2021
Statut: ppublish

Résumé

Several severe acute respiratory syndrome coronavirus 2 variants of concern (VOCs) emerged in late 2020; lineage B.1.1.7 initially dominated globally. However, lineages B.1.351 and P.1 represent potentially greater risk for transmission and immune escape. In British Columbia, Canada, B.1.1.7 and B.1.351 were first identified in December 2020 and P.1 in February 2021. We combined quantitative PCR and whole-genome sequencing to assess relative contribution of VOCs in nearly 67,000 infections during the first 16 weeks of 2021 in British Columbia. B.1.1.7 accounted for <10% of screened or sequenced specimens early on, increasing to >50% by week 8. P.1 accounted for <10% until week 10, increased rapidly to peak at week 12, and by week 13 codominated within 10% of rates of B.1.1.7. B.1.351 was a minority throughout. This rapid expansion of P.1 but suppression of B.1.351 expands our understanding of population-level VOC patterns and might provide clues to fitness determinants for emerging VOCs.

Identifiants

pubmed: 34388358
doi: 10.3201/eid2711.211190
pmc: PMC8544957
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2802-2809

Références

Emerg Infect Dis. 2021 Jun;27(6):1673-1676
pubmed: 33784237
JAMA. 2021 Mar 16;325(11):1037-1038
pubmed: 33595644
N Engl J Med. 2021 Jun 10;384(23):2212-2218
pubmed: 33882219
Science. 2021 Mar 12;371(6534):1152-1153
pubmed: 33514629
BMJ. 2021 Mar 9;372:n579
pubmed: 33687922
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
Viruses. 2021 Apr 29;13(5):
pubmed: 33946747
Wellcome Open Res. 2021 May 19;6:121
pubmed: 34095513
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):95-99
pubmed: 33476315
Nat Med. 2021 Apr;27(4):717-726
pubmed: 33664494
Lancet Infect Dis. 2021 Sep;21(9):1246-1256
pubmed: 33857406

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH